

# Janusz A Jankowski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8201089/publications.pdf>

Version: 2024-02-01

263  
papers

22,855  
citations

16437

64  
h-index

8618

146  
g-index

317  
all docs

317  
docs citations

317  
times ranked

29325  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011, 476, 214-219.	13.7	2,400
2	Genome-wide association analysis identifies 13 new risk loci for schizophrenia. <i>Nature Genetics</i> , 2013, 45, 1150-1159.	9.4	1,395
3	British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. <i>Gut</i> , 2014, 63, 7-42.	6.1	1,116
4	The Development and Validation of an Endoscopic Grading System for Barrett's Esophagus: The Prague C & M Criteria. <i>Gastroenterology</i> , 2006, 131, 1392-1399.	0.6	931
5	A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. <i>Nature Genetics</i> , 2010, 42, 985-990.	9.4	918
6	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. <i>Nature Genetics</i> , 2012, 44, 1341-1348.	9.4	848
7	Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. <i>Nature Genetics</i> , 2011, 43, 761-767.	9.4	778
8	Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. <i>Lancet Oncology</i> , The, 2009, 10, 501-507.	5.1	642
9	A clinical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop 1 1 Members of the workshop composed a group of international experts in BE from gastroenterology, surgery, pathology, molecular biology, outcomes, and epidemiology. Conference chairman: Prateek Sharma; conference moderator: Kenneth McQuaid; group leaders: John Dent, M. Brian Fennerty, Richard Sampliner, Stuart Spechler; participants: Alan Cameron, Douglas Corley, Gary Falk, John Goldblum, John Hunter, Janusz Ja. <i>Gastroenterology</i> , 2004, 127, 310-330.	0.6	579
10	Guidelines for the management of oesophageal and gastric cancer. <i>Gut</i> , 2011, 60, 1449-1472.	6.1	570
11	Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. <i>Nature Genetics</i> , 2009, 41, 1330-1334.	9.4	483
12	Genome-wide meta-analyses of multiancestry cohorts identify multiple new susceptibility loci for refractive error and myopia. <i>Nature Genetics</i> , 2013, 45, 314-318.	9.4	398
13	Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. <i>Nature Genetics</i> , 2011, 43, 117-120.	9.4	390
14	Molecular Evolution of the Metaplasia-Dysplasia-Adenocarcinoma Sequence in the Esophagus. <i>American Journal of Pathology</i> , 1999, 154, 965-973.	1.9	380
15	Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. <i>Nature Genetics</i> , 2012, 44, 328-333.	9.4	375
16	Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process. <i>Gastroenterology</i> , 2012, 143, 336-346.	0.6	365
17	Barrett's metaplasia. <i>Lancet</i> , The, 2000, 356, 2079-2085.	6.3	315
18	Germline E-cadherin Gene (CDH1) Mutations Predispose to Familial Gastric Cancer and Colorectal Cancer. <i>Human Molecular Genetics</i> , 1999, 8, 607-610.	1.4	312

#	ARTICLE	IF	CITATIONS
19	Estimates of benefits and harms of prophylactic use of aspirin in the general population. <i>Annals of Oncology</i> , 2015, 26, 47-57.	0.6	303
20	Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. <i>Lancet Oncology</i> , The, 2014, 15, 894-904.	5.1	270
21	Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 714-719.	3.3	269
22	Detection of Intestinal Metaplasia in Barrett's Esophagus: An Observational Comparator Study Suggests the Need for a Minimum of Eight Biopsies. <i>American Journal of Gastroenterology</i> , 2007, 102, 1154-1161.	0.2	242
23	Mechanisms of Field Cancerization in the Human Stomach: The Expansion and Spread of Mutated Gastric Stem Cells. <i>Gastroenterology</i> , 2008, 134, 500-510.	0.6	222
24	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. <i>Nature Communications</i> , 2014, 5, 5068.	5.8	216
25	Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. <i>Human Molecular Genetics</i> , 2011, 20, 345-353.	1.4	202
26	Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. <i>Gut</i> , 2008, 57, 1041-1048.	6.1	182
27	Tumour necrosis factor- $\alpha$ in Barrett's oesophagus: a potential novel mechanism of action. <i>Oncogene</i> , 2002, 21, 6071-6081.	2.6	180
28	Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. <i>Human Molecular Genetics</i> , 2012, 21, 4996-5009.	1.4	176
29	Clonality, Founder Mutations, and Field Cancerization in Human Ulcerative Colitis-Associated Neoplasia. <i>Gastroenterology</i> , 2009, 136, 542-550.e6.	0.6	164
30	Common Genetic Determinants of Intraocular Pressure and Primary Open-Angle Glaucoma. <i>PLoS Genetics</i> , 2012, 8, e1002611.	1.5	164
31	Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. <i>Nature Genetics</i> , 2012, 44, 1131-1136.	9.4	162
32	RHBDF2 Mutations Are Associated with Tylosis, a Familial Esophageal Cancer Syndrome. <i>American Journal of Human Genetics</i> , 2012, 90, 340-346.	2.6	162
33	Genome-Wide Association Study Implicates HLA-C*01:02 as a Risk Factor at the Major Histocompatibility Complex Locus in Schizophrenia. <i>Biological Psychiatry</i> , 2012, 72, 620-628.	0.7	156
34	Evidence for hypomotility in non-ulcer dyspepsia: a prospective multifactorial study.. <i>Gut</i> , 1991, 32, 246-251.	6.1	155
35	Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas. <i>Clinical Cancer Research</i> , 2006, 12, 4283-4287.	3.2	154
36	Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. <i>Gastroenterology</i> , 2003, 124, 615-625.	0.6	152

#	ARTICLE	IF	CITATIONS
37	Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. <i>American Journal of Pathology</i> , 1998, 152, 135-44.	1.9	149
38	Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. <i>Lancet Oncology</i> , The, 2016, 17, 1363-1373.	5.1	133
39	Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. <i>Gut</i> , 2003, 52, 174-180.	6.1	132
40	Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer – Differential treatment strategies for subtypes of early gastroesophageal cancer. <i>European Journal of Cancer</i> , 2012, 48, 2941-2953.	1.3	129
41	Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus.. <i>Gut</i> , 1992, 33, 1033-1038.	6.1	127
42	Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. <i>Gastroenterology</i> , 2002, 122, 588-590.	0.6	124
43	A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response. <i>Clinical Cancer Research</i> , 2007, 13, 5869-5875.	3.2	120
44	Clonality Assessment and Clonal Ordering of Individual Neoplastic Crypts Shows Polyclonality of Colorectal Adenomas. <i>Gastroenterology</i> , 2010, 138, 1441-1454.e7.	0.6	118
45	BOB CAT: a Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. <i>American Journal of Gastroenterology</i> , 2015, 110, 662-682.	0.2	116
46	Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours. <i>Journal of Clinical Pathology</i> , 1999, 52, 151-157.	2.1	115
47	Management of Barrett's Esophagus in the UK: Overtreated and Underbiopsied but Improved by the Introduction of a National Randomized Trial. <i>American Journal of Gastroenterology</i> , 2008, 103, 1079-1089.	0.2	113
48	Polymorphisms Near TBX5 and GDF7 Are Associated With Increased Risk for Barrett's Esophagus. <i>Gastroenterology</i> , 2015, 148, 367-378.	0.6	93
49	Chemoprevention of Oesophageal Cancer and the AspECT Trial. <i>Recent Results in Cancer Research</i> , 2009, 181, 161-169.	1.8	91
50	ABC of colorectal cancer: Molecular basis for risk factors. <i>BMJ: British Medical Journal</i> , 2000, 321, 886-889.	2.4	90
51	Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial. <i>BMJ: British Medical Journal</i> , 2008, 337, a2664-a2664.	2.4	89
52	Meta-analysis of genome-wide association studies identifies novel loci that influence cupping and the glaucomatous process. <i>Nature Communications</i> , 2014, 5, 4883.	5.8	89
53	Common variants in the HLA-DRB1/HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. <i>Nature Genetics</i> , 2013, 45, 208-213.	9.4	86
54	Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer. <i>Oncogene</i> , 2002, 21, 1928-1933.	2.6	85

#	ARTICLE	IF	CITATIONS
55	The Clonal Origins of Dysplasia From Intestinal Metaplasia in the Human Stomach. <i>Gastroenterology</i> , 2011, 140, 1251-1260.e6.	0.6	80
56	Abnormal expression of growth regulatory factors in Barrett's oesophagus. <i>Clinical Science</i> , 1991, 81, 663-668.	1.8	79
57	An Antiapoptotic Role for Gastrin and the Gastrin/CCK-2 Receptor in Barrett's Esophagus. <i>Cancer Research</i> , 2004, 64, 1915-1919.	0.4	79
58	In vivo analysis of gut function and disease changes in a zebrafish larvae model of inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1162-1172.	0.9	79
59	Failure to Validate Association between 12p13 Variants and Ischemic Stroke. <i>New England Journal of Medicine</i> , 2010, 362, 1547-1550.	13.9	75
60	Mortality rates in patients with Barrett's oesophagus. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 316-320.	1.9	74
61	Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett's oesophagus and provides insights into clinical heterogeneity in reflux diagnosis. <i>Gut</i> , 2022, 71, 1053-1061.	6.1	74
62	Chemoprevention of Colorectal Cancer. <i>Digestion</i> , 2007, 76, 51-67.	1.2	72
63	Barrett's metaplasia glands are clonal, contain multiple stem cells and share a common squamous progenitor. <i>Gut</i> , 2012, 61, 1380-1389.	6.1	72
64	The correlation between reading and mathematics ability at age twelve has a substantial genetic component. <i>Nature Communications</i> , 2014, 5, 4204.	5.8	72
65	Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study. <i>Journal of Pathology</i> , 1999, 187, 535-540.	2.1	70
66	Mechanisms of Disease: from stem cells to colorectal cancer. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2006, 3, 267-274.	1.7	67
67	The stem cell organisation, and the proliferative and gene expression profile of Barrett's epithelium, replicates pyloric-type gastric glands. <i>Gut</i> , 2014, 63, 1854-1863.	6.1	66
68	Ectopic Expression of P-Cadherin Correlates with Promoter Hypomethylation Early in Colorectal Carcinogenesis and Enhanced Intestinal Crypt Fission <i>In vivo</i> . <i>Cancer Research</i> , 2008, 68, 7760-7768.	0.4	64
69	Identification of Lineage-Uncommitted, Long-Lived, Label-Retaining Cells in Healthy Human Esophagus and Stomach, and in Metaplastic Esophagus. <i>Gastroenterology</i> , 2013, 144, 761-770.	0.6	63
70	Epidermal growth factor receptors in the oesophagus. <i>Gut</i> , 1992, 33, 439-443.	6.1	62
71	Proliferating cell nuclear antigen in oesophageal diseases; correlation with transforming growth factor alpha expression. <i>Gut</i> , 1992, 33, 587-591.	6.1	59
72	Association of transforming growth factor alpha (TGFA) and its precursors with malignant change in Barrett's epithelium: Biological and clinical variables. <i>International Journal of Cancer</i> , 1995, 60, 27-32.	2.3	59

#	ARTICLE	IF	CITATIONS
73	Biomarkers in Gastroenterology: Between Hope and Hype Comes Histopathology. American Journal of Gastroenterology, 2009, 104, 1093-1096.	0.2	58
74	Conditional analysis identifies three novel major histocompatibility complex loci associated with psoriasis. Human Molecular Genetics, 2012, 21, 5185-5192.	1.4	58
75	Gastroesophageal reflux GWAS identifies risk loci that also associate with subsequent severe esophageal diseases. Nature Communications, 2019, 10, 4219.	5.8	58
76	Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: <i>ex vivo</i> and <i>in vitro</i> studies. Journal of Pathology, 2008, 215, 184-194.	2.1	57
77	Aberrant P-cadherin expression is an early event in hyperplastic and dysplastic transformation in the colon. Gut, 2002, 50, 513-519.	6.1	56
78	Behçet's syndrome in Scotland. Postgraduate Medical Journal, 1992, 68, 566-570.	0.9	55
79	Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study. BMJ: British Medical Journal, 2009, 339, b2576-b2576.	2.4	54
80	Diagnosis and management of Barrett's oesophagus. BMJ: British Medical Journal, 2010, 341, c4551-c4551.	2.4	53
81	Expression of transforming growth factor alpha, epidermal growth factor receptor and epidermal growth factor in precursor lesions to gastric carcinoma. British Journal of Cancer, 1995, 71, 30-36.	2.9	52
82	Analysis of the clonal architecture of the human small intestinal epithelium establishes a common stem cell for all lineages and reveals a mechanism for the fixation and spread of mutations. Journal of Pathology, 2009, 217, 489-496.	2.1	52
83	Epidermal growth factor in the oesophagus.. Gut, 1992, 33, 1448-1453.	6.1	51
84	Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention. Colorectal Disease, 2008, 10, 244-248.	0.7	51
85	Development of quality indicators for endoscopic eradication therapies in Barrett's oesophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Oesophagus) Consortium. Gastrointestinal Endoscopy, 2017, 86, 1-17.e3.	0.5	50
86	Flow-Cytometric Analysis of Growth-Regulatory Peptides and Their Receptors in Barrett's Oesophagus and Oesophageal Adenocarcinoma. Scandinavian Journal of Gastroenterology, 1992, 27, 147-154.	0.6	47
87	Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base. BMJ: British Medical Journal, 2006, 332, 1512.1.	2.4	47
88	Expression of Epidermal Growth Factor, Transforming Growth Factor Alpha and Their Receptor in Gastro-Oesophageal Diseases. Digestive Diseases, 1993, 11, 1-11.	0.8	46
89	Re: Cost-Effectiveness of Aspirin Chemoprevention for Barrett's Esophagus. Journal of the National Cancer Institute, 2004, 96, 885-887.	3.0	46
90	The role of ATM in response to metformin treatment and activation of AMPK. Nature Genetics, 2012, 44, 359-360.	9.4	46

#	ARTICLE	IF	CITATIONS
91	Effect of Ectopic Expression of Rat Trefoil Factor Family 3 (Intestinal Trefoil Factor) in the Jejunum of Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2001, 276, 24088-24096.	1.6	45
92	Barrett's Oesophagus Surveillance versus endoscopy at need Study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. <i>Journal of Medical Screening</i> , 2015, 22, 158-164.	1.1	45
93	Sequential changes in cadherin-catenin expression associated with the progression and heterogeneity of primary oesophageal squamous carcinoma. , 1998, 79, 573-579.		43
94	Gastro-oesophageal cancer: death at the junction. <i>BMJ: British Medical Journal</i> , 2000, 321, 463-464.	2.4	43
95	Clonal Expansion in the Human Gut: Mitochondrial DNA Mutations Show Us the Way. <i>Cell Cycle</i> , 2006, 5, 808-811.	1.3	43
96	Expression of the trefoil peptides pS2 and human spasmodic polypeptide (hSP) in Barrett's metaplasia and the native oesophageal epithelium: Delineation of epithelial phenotype. <i>Journal of Pathology</i> , 1994, 173, 213-219.	2.1	42
97	Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in Kenyan Children. <i>American Journal of Human Genetics</i> , 2016, 98, 1092-1100.	2.6	39
98	A comprehensive re-assessment of the association between vitamin D and cancer susceptibility using Mendelian randomization. <i>Nature Communications</i> , 2021, 12, 246.	5.8	39
99	Review article: management of oesophageal adenocarcinoma - control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 71-80.	1.9	38
100	Genetics of Gastroesophageal Cancer: Paradigms, Paradoxes, and Prognostic Utility. <i>American Journal of Gastroenterology</i> , 2008, 103, 443-449.	0.2	38
101	Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. <i>American Journal of Gastroenterology</i> , 2017, 112, 1032-1048.	0.2	38
102	Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. <i>Gut</i> , 2017, 66, 1739-1747.	6.1	38
103	Gene expression in Barrett's mucosa: acute and chronic adaptive responses in the oesophagus.. <i>Gut</i> , 1993, 34, 1649-1650.	6.1	37
104	Maintenance of normal intestinal mucosa: function, structure, and adaptation.. <i>Gut</i> , 1994, 35, S1-S4.	6.1	37
105	Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Counterpoint. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1858-1861.	1.1	37
106	Aberrant P-cadherin expression is a feature of clonal expansion in the gastrointestinal tract associated with repair and neoplasia. , 2000, 190, 526-530.		36
107	Met Receptor Signaling: A Key Effector in Esophageal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 5936-5943.	3.2	34
108	Molecular pathways in bladder cancer: Part 1. <i>BJU International</i> , 2005, 95, 485-490.	1.3	33



#	ARTICLE	IF	CITATIONS
109	Molecular biology of Barrett's cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2006, 20, 813-827.	1.0	32
110	Hyperplastic polyps: a cell lineage which both synthesizes and secretes trefoil-peptides and has phenotypic similarity with the ulcer-associated cell lineage. <i>American Journal of Pathology</i> , 1993, 142, 663-8.	1.9	32
111	The Administration of Supplementary Oxygen to Prevent Hypoxia During Upper Alimentary Endoscopy. <i>Endoscopy</i> , 1993, 25, 269-273.	1.0	31
112	A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2006, 3, 101-111.	1.7	31
113	The Evidence Base of Proton Pump Inhibitor Chemopreventative Agents in Barrett's Esophagus – The Good, The Bad, and The Flawed!. <i>American Journal of Gastroenterology</i> , 2007, 102, 21-23.	0.2	31
114	Increased expression of epidermal growth factor receptors in Barrett's esophagus associated with alkaline reflux: a putative model for carcinogenesis. <i>American Journal of Gastroenterology</i> , 1993, 88, 402-8.	0.2	31
115	Barrett's Esophagus: Disregulation of Cell Cycling and Intercellular Adhesion in the Metaplasia-Dysplasia-Carcinoma Sequence. <i>Digestion</i> , 2000, 61, 1-5.	1.2	29
116	Gastroesophageal reflux disease and bulimia nervosa - a review of the literature. <i>Ecological Management and Restoration</i> , 2011, 24, 79-85.	0.2	29
117	Genome-wide association study of intraocular pressure identifies the GLCCI1/ICA1 region as a glaucoma susceptibility locus. <i>Human Molecular Genetics</i> , 2013, 22, 4653-4660.	1.4	29
118	Molecular pathways in bladder cancer: Part 2. <i>BJU International</i> , 2005, 95, 491-496.	1.3	27
119	Barrett's esophagus: an overview of the molecular biology *. <i>Ecological Management and Restoration</i> , 1999, 12, 177-180.	0.2	26
120	The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus. <i>Journal of Clinical Pathology</i> , 2004, 57, 1156-1159.	1.0	26
121	Growth Factors and Oncogenes in Barrett's Oesophagus and Gastric Metaplasia. <i>Endoscopy</i> , 1993, 25, 637-641.	1.0	25
122	Changes in Gene Structure and Regulation of E-Cadherin during Epithelial Development, Differentiation, and Disease. <i>Progress in Molecular Biology and Translational Science</i> , 1997, 57, 187-215.	1.9	25
123	Approaches to Barrett's oesophagus treatment-the role of proton pump inhibitors and other interventions. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 54-59.	1.9	25
124	Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo. <i>Gut</i> , 2010, 59, 156-163.	6.1	25
125	Barrett's mucosa: remodelling by the microenvironment. <i>Journal of Pathology</i> , 2000, 192, 1-3.	2.1	23
126	Aspirin and NSAIDs; benefits and harms for the gut. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 197-206.	1.0	23



#	ARTICLE	IF	CITATIONS
127	Transforming growth factor alpha in epithelial proliferative diseases of the breast.. Journal of Clinical Pathology, 1992, 45, 513-516.	1.0	22
128	A family history of Barrett's oesophagus: Another risk factor?. Scandinavian Journal of Gastroenterology, 2005, 40, 1127-1128.	0.6	22
129	Growth regulatory peptides in gastric mucosa. Clinical Science, 1992, 82, 581-587.	1.8	21
130	Esophageal Adenocarcinoma in "Mice and Men" Back to Basics!. American Journal of Gastroenterology, 2008, 103, 2367-2372.	0.2	21
131	Comparing virtual with conventional microscopy for the consensus diagnosis of Barrett's neoplasia in the AspECT Barrett's chemoprevention trial pathology audit. Histopathology, 2012, 61, 795-800.	1.6	21
132	Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's oesophagus. The Cochrane Library, 2012, 11, CD007334.	1.5	20
133	Acid Suppression and Chemoprevention in Barrett's Oesophagus. Digestive Diseases, 2004, 22, 171-180.	0.8	19
134	Molecular changes in the progression of Barrett's oesophagus. Postgraduate Medical Journal, 2007, 83, 529-535.	0.9	17
135	Physiological and molecular analysis of acid loading mechanisms in squamous and columnar-lined esophagus. Ecological Management and Restoration, 2008, 21, 529-538.	0.2	17
136	Cytoplasmic $\beta$ -catenin accumulation is a good prognostic marker in upper and lower gastrointestinal adenocarcinomas. Histopathology, 2010, 57, 101-111.	1.6	16
137	No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. Clinical Gastroenterology and Hepatology, 2019, 17, 2227-2235.e1.	2.4	16
138	Epithelial stem cells in gastrointestinal morphogenesis, adaptation and carcinogenesis. Seminars in Cell Biology, 1992, 3, 445-456.	3.5	15
139	Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib. Journal of Clinical Oncology, 2004, 22, 4021-4021.	0.8	15
140	DIFFERENTIAL EXPRESSION OF E-CADHERIN IN NORMAL, METAPLASTIC AND DYSPLASTIC ESOPHAGEAL MUCOSA - A PUTATIVE BIOMARKER. International Journal of Oncology, 1994, 4, 441-8.	1.4	14
141	Transient P-cadherin expression in radiation proctitis; a model of mucosal injury and repair. Journal of Pathology, 2002, 197, 194-200.	2.1	14
142	Chemoprevention in Barrett's Esophagus: A Pill a Day?. Gastrointestinal Endoscopy Clinics of North America, 2011, 21, 155-170.	0.6	14
143	Acid Reflux and Oesophageal Cancer. Recent Results in Cancer Research, 2011, 185, 65-82.	1.8	14
144	Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib. Journal of Clinical Oncology, 2004, 22, 4021-4021.	0.8	14

#	ARTICLE	IF	CITATIONS
145	Chemoprevention in Barrett's oesophagus. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 569-579.	1.0	13
146	Does long term aspirin prevent cancer?. <i>BMJ: British Medical Journal</i> , 2010, 341, c7326-c7326.	2.4	13
147	Barrett's Esophagus: Diagnosis, Screening, Surveillance, and Controversies. <i>Gut and Liver</i> , 2007, 1, 93-100.	1.4	13
148	Improved silver staining of nucleolar organiser regions in paraffin wax sections using an inverted incubation technique.. <i>Journal of Clinical Pathology</i> , 1990, 43, 1029-1031.	1.0	12
149	Drinking from the fountain of promise: biomarkers in the surveillance of Barrett's oesophagus--the glass is half full!. <i>Gut</i> , 2006, 55, 1377-1379.	6.1	12
150	Genetic variation in VAC14 is associated with bacteremia secondary to diverse pathogens in African children. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3601-E3603.	3.3	12
151	The treatment, management and prevention of oesophageal cancer. <i>Expert Opinion on Biological Therapy</i> , 2001, 1, 1017-1028.	1.4	11
152	A feasibility trial of Acetic acid-targeted Biopsies versus nontargeted quadrant biopsies during Barrett's surveillance: the ABBA trial. <i>Endoscopy</i> , 2020, 52, 29-36.	1.0	11
153	Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. <i>Carcinogenesis</i> , 2021, 42, 369-377.	1.3	11
154	Glucose-6-phosphatase in normal adult human intestinal mucosa. <i>Clinical Science</i> , 1992, 83, 683-687.	1.8	10
155	Development and growth of normal; metaplastic and dysplastic oesophageal mucosa. <i>European Journal of Gastroenterology and Hepatology</i> , 1993, 5, 235-246.	0.8	10
156	The continuing tale of cytokeratins in Barrett's mucosa: As you like it. <i>Gut</i> , 2001, 49, 746-747.	6.1	10
157	Hypercalcaemia in rheumatoid arthritis revisited.. <i>Annals of the Rheumatic Diseases</i> , 1990, 49, 22-24.	0.5	9
158	Uptake of horseradish peroxidase by human oesophageal explants over 24 h. <i>The Histochemical Journal</i> , 1991, 23, 409-414.	0.6	9
159	Flow cytometry of oesophageal mucosal biopsies; epidermal growth factor receptor, and CD15. <i>Journal of Pathology</i> , 1992, 167, 321-326.	2.1	9
160	Barrett's Esophagus: Environmental Influences in the Progression of Dysplasia. <i>World Journal of Surgery</i> , 2003, 27, 1014-1017.	0.8	9
161	Surgery versus radical endotherapies for early cancer and high grade dysplasia in Barrett's oesophagus. , 2009, , CD007334.		9
162	Aspirin in the prevention of cancer. <i>Lancet</i> , The, 2011, 377, 1649-1650.	6.3	9

#	ARTICLE	IF	CITATIONS
163	Helicobacter pylori infection and gastric cancer.. BMJ: British Medical Journal, 1991, 302, 1534-1534.	2.4	8
164	Secretory and absorptive activity of oesophageal epithelium: evidence of circulating mucosubstances. The Histochemical Journal, 1994, 26, 41-49.	0.6	8
165	Cadherin adhesion in the intestinal crypt regulates morphogenesis, mitogenesis, motogenesis, and metaplasia formation. Journal of Clinical Pathology, 1999, 52, 166-168.	2.1	8
166	Does aspirin really reduce the risk of colon cancer?. Lancet, The, 2012, 379, 1586-1587.	6.3	8
167	Aspirin chemoprevention of gastrointestinal cancer in the next decade. A review of the evidence. Polish Archives of Internal Medicine, 2010, 120, 407-412.	0.3	8
168	Chemoprevention and Barrett's Esophagus: Decisions, Decisions. American Journal of Gastroenterology, 2008, 103, 2443-2445.	0.2	7
169	Editorial: Dissecting GI Phenotypeâ€“Genotype Relationships in GERD and Dyspepsia: An SNP Here and an SNP There!. American Journal of Gastroenterology, 2009, 104, 286-288.	0.2	7
170	Barrett's Esophagus: Evolutionary Insights From Genomics. Gastroenterology, 2013, 144, 667-669.	0.6	7
171	Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 427-433.	1.1	7
172	Self-assessment of medical knowledge: do physicians overestimate or underestimate?. Journal of the Royal College of Physicians of London, 1991, 25, 306-8.	0.2	7
173	Altered gene expression of growth factors and their receptors during esophageal tumorigenesis. Gastroenterologie Clinique Et Biologique, 1994, 18, D40-5.	0.9	7
174	Gastro-Esophageal Reflux Disease and Bile Acids. Journal of Pediatric Gastroenterology and Nutrition, 2003, 36, 172-174.	0.9	6
175	The effect of alginates on deoxycholic-acid-induced changes in oesophageal mucosal biology at pH 4. Journal of Biomaterials Science, Polymer Edition, 2007, 18, 317-333.	1.9	6
176	Editorial: One Small Step for Metaplasia, but One Giant Leap for Biomarkers Is Needed. American Journal of Gastroenterology, 2009, 104, 2681-2683.	0.2	6
177	Surgery versus radical endotherapies for early cancer and high grade dysplasia in Barrett's oesophagus. , 2010, , CD007334.		6
178	Trefoil Factor Expression in a Human Model of the Early Stages of Barrettâ€™s Esophagus. Digestive Diseases and Sciences, 2015, 60, 1187-1194.	1.1	6
179	An assessment of candidate genes to assist prognosis in gastric cancer. Journal of Gastrointestinal Oncology, 2018, 9, 303-310.	0.6	6
180	Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals. Human Genetics and Genomics Advances, 2021, 2, 100041.	1.0	6

#	ARTICLE	IF	CITATIONS
181	Oesophageal carcinoma. <i>European Journal of Cancer Prevention</i> , 1993, 2, 5-12.	0.6	5
182	A colorectal cell line with alterations in E-cadherin and epithelial biology may be an in vitro model of colitis. <i>Journal of Clinical Pathology</i> , 1999, 52, 231-242.	2.1	5
183	NSAID and oesophageal adenocarcinoma: randomised trials needed to correct for bias. <i>Lancet Oncology</i> , The, 2006, 7, 7-8.	5.1	5
184	Endoscopic therapies for the prevention and treatment of early esophageal neoplasia. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011, 5, 731-743.	1.4	5
185	Molecular events in Barrett's metaplasia. <i>Gastroenterology</i> , 1993, 104, 1235.	0.6	4
186	Morphological analysis of gastro-esophageal diseases by molecular cell techniques. <i>Microscopy Research and Technique</i> , 1995, 31, 184-192.	1.2	4
187	Aspirin therapy for cancer: it is never too late. <i>British Journal of Cancer</i> , 2011, 105, 1105-1106.	2.9	4
188	Adenocarcinoma and Barrett's oesophagus.. <i>Gut</i> , 1992, 33, 862-863.	6.1	3
189	Molecular surveillance of Barrett's esophagus and putative strategies for genetic therapy. <i>Ecological Management and Restoration</i> , 1995, 8, 113-118.	0.2	3
190	Adenocarcinoma in Barrett Esophagus. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, S129-S134.	1.1	3
191	Liver transplantation in patients with alcoholic cirrhosis.. <i>BMJ: British Medical Journal</i> , 1990, 301, 390-390.	2.4	2
192	Cardiorespiratory effects during gastrointestinal endoscopy. <i>Anaesthesia</i> , 1991, 46, 698-698.	1.8	2
193	Flow-cytometric assessment of regulatory peptides in Barrett's mucosa. <i>Gastroenterology</i> , 1992, 103, 1121.	0.6	2
194	Curing oesophageal cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 1173-1175.	0.8	2
195	10-minute consultation: Gastro-oesophageal reflux disease. <i>BMJ: British Medical Journal</i> , 2002, 325, 945-945.	2.4	2
196	Premalignant Lesions of the Oesophagus: Identification to Management. , 2005, , 259-269.		2
197	Cancer prevention. <i>BMJ: British Medical Journal</i> , 2005, 331, 618.	2.4	2
198	Genetics of inflammatory bowel disease and associated cancers. <i>Current Colorectal Cancer Reports</i> , 2006, 2, 191-199.	1.0	2

#	ARTICLE	IF	CITATIONS
199	Chemoprevention of gastrointestinal cancer. <i>British Journal of Surgery</i> , 2008, 95, 674-676.	0.1	2
200	Prevention of colorectal cancer by combining early detection and chemoprevention. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 48-54.	1.0	2
201	Editorial: Genetics of Barrett's: The Bigger, the Better. <i>American Journal of Gastroenterology</i> , 2012, 107, 1342-1345.	0.2	2
202	Tipping the Balance: Benefits and Risks of Aspirin in Chemoprevention of Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 1-8.	1.0	2
203	Why is There a Change in Patterns of GE Cancer?. <i>Recent Results in Cancer Research</i> , 2012, 196, 115-140.	1.8	2
204	Down-regulation of E-cadherin and $\beta$ -catenin in Helicobacter pylori Associated Gastritis and Gastric Carcinoma: An Immunohistochemical Study. <i>Gastrointestinal Oncology</i> , 2002, 4, 203-208.	0.1	2
205	Management of Barrett esophagus: a practical guide for clinicians based on the BADCAT and BoB CAT recommendations. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 765-770.	0.3	2
206	Changes in Keratan Sulphate Levels in the Serum of a Long Distance Runner. <i>Rheumatology</i> , 1990, 29, 314-315.	0.9	1
207	Screening for alimentary cancer. <i>European Journal of Cancer Prevention</i> , 1993, 2, 211-214.	0.6	1
208	Cell cycle abnormalities in Barrett's esophagus: Further insights. <i>Gastroenterology</i> , 1994, 106, 553.	0.6	1
209	The role of receptor tyrosine kinase inhibition in treating gastrointestinal malignancy. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 577-592.	1.9	1
210	Commentary: The relation of obesity, reflux and its implications. <i>International Journal of Epidemiology</i> , 2003, 32, 650-651.	0.9	1
211	Chemoprevention for Barrett's Esophagus. , 0, , 236-252.		1
212	Detection of Intestinal Metaplasia in Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2007, 102, 2353-2354.	0.2	1
213	Hyperplastic polyps, serrated adenomas, and the serrated polyp neoplasia pathway. <i>Current Colorectal Cancer Reports</i> , 2007, 3, 3-9.	1.0	1
214	Mortality risks associated with Barrett's oesophagus: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 853-854.	1.9	1
215	Aspirin in the primary prevention of vascular disease. <i>Lancet, The</i> , 2009, 374, 877-878.	6.3	1
216	PWE-065...Investigating clonal competition in Barrett's associated tumorigenesis using spatial maps of genetic heterogeneity. <i>Gut</i> , 2010, 59, A111.1-A111.	6.1	1

#	ARTICLE	IF	CITATIONS
217	The field effect in Barrett's esophagus: can we use it for screening and surveillance?. <i>Endoscopy</i> , 2013, 45, 989-991.	1.0	1
218	Sequential changes in cadherin-catenin expression associated with the progression and heterogeneity of primary oesophageal squamous carcinoma. <i>International Journal of Cancer</i> , 1998, 79, 573-579.	2.3	1
219	The Prevalence of Ischaemic Heart Disease in Patients in an Endoscopic Barrett's Cancer Surveillance Program: A UK Pilot Study. <i>Gastrointestinal Oncology</i> , 2002, 4, 199-201.	0.1	1
220	Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's esophagus. <i>The Cochrane Library</i> , 2020, 2020, CD007334.	1.5	1
221	eQTL set-based association analysis identifies novel susceptibility loci for Barrett's esophagus and esophageal adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 0, , .	1.1	1
222	Epidermal Growth Factor in the Oesophagus. <i>Clinical Science</i> , 1991, 80, 6P-6P.	0.0	0
223	Growth factors: potential for the management of solid epithelial tumours. <i>Bailliere's Clinical Gastroenterology</i> , 1996, 10, 165-179.	0.9	0
224	Squamous carcinoma oesophagus: continuing to challenge. <i>Digestive and Liver Disease</i> , 2001, 33, 528-530.	0.4	0
225	Role of salivary epidermal growth factor in the pathogenesis of Barrett's columnar lined oesophagus. <i>British Journal of Surgery</i> , 2005, 79, 716-716.	0.1	0
226	Corrigendum to: The effect of alginates on deoxycholic-acid-induced changes in oesophageal mucosal biology at pH 4. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2007, 18, 939-939.	1.9	0
227	Neuroendocrine Tumors. , 0, , 564-668.		0
228	Epidemiology of Hepatocellular Carcinoma. , 0, , 409-420.		0
229	Nonsteroidal anti-inflammatories (NSAIDs) and aspirin for intestinal metaplasia of the stomach. <i>The Cochrane Library</i> , 2010, , .	1.5	0
230	Gastroenterology research: where now?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 655-659.	1.4	0
231	Treatment of squamous cell and adenocarcinoma of the esophagus. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2012, , 39.	5.5	0
232	OC-030...Barrett's Epithelium Shows Evidence of Gastric and Intestinal Differentiation Programmes but Preserves the Proliferative and Stem Cell Architecture of Gastric Glands. <i>Gut</i> , 2013, 62, A13.2-A13.	6.1	0
233	Response to Feuerstein J et al. "Systematic Analysis and Critical Appraisal of the Quality of the Scientific Evidence and Conflicts of Interest in Practice Guidelines (2005-2013) for Barrett's Esophagus"; doi:10.1007/s10620-016-4222-2. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3369-3371.	1.1	0
234	Chemoprevention of Cancer: An Overview of Promising Agents and Current Research. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
235	Differential T-cell responses in the pathogenesis of Barrett's metaplasia: A cephalo-caudal and surface to crypt gradient. <i>Gastroenterology</i> , 2001, 120, A444-A444.	0.6	0
236	Superficial Esophageal Cancer: Adenocarcinoma Related to Barrett's Metaplasia and Adenoid Cystic Carcinoma. , 2002, , 169-180.		0
237	<i>Gastroenterology</i> . <i>BMJ: British Medical Journal</i> , 2002, 325, 113Sa-113.	2.4	0
238	The Role of Drugs and Nutrition in the Prevention of Esophageal Adenocarcinoma Associated with Barrett's Esophagus. , 2007, , 17-31.		0
239	Chemoprevention for Esophageal Carcinoma. , 2015, , 83-91.		0
240	Barrett's Esophagus: Pathogenesis and Prevention. , 2017, , 11-16.		0
241	Chemoprevention of Esophageal Cancer. , 2020, , 113-125.		0
242	Recent advances in understanding and preventing oesophageal cancer. <i>F1000Research</i> , 2020, 9, 276.	0.8	0
243	Aspirin chemoprevention in barrett esophagus: is the risk worth the benefit?. <i>Gastroenterology and Hepatology</i> , 2012, 8, 831-3.	0.2	0
244	Epidemiology of Gastroesophageal Cancer. , 0, , 1-13.		0
245	Rare Tumors of the Abdomen. , 0, , 259-289.		0
246	Epidemiology and Prevention of Colorectal Cancer. , 0, , 291-304.		0
247	The Molecular Pathology of Sporadic and Hereditary Colorectal Cancer. , 0, , 305-316.		0
248	Cancer of the Colon and Rectum. , 0, , 325-373.		0
249	Factors Involved in Carcinogenesis and Prevention in Hepatobiliary Cancer. , 0, , 421-432.		0
250	Molecular Biology of Hepatobiliary Cancer. , 0, , 433-440.		0
251	Primary Liver Cancer. , 0, , 441-468.		0
252	Factors Involved in Carcinogenesis and Prevention. , 0, , 14-20.		0



#	ARTICLE	IF	CITATIONS
253	Metastatic Liver Cancer. , 0, , 469-497.		0
254	Primary Pancreatic Adenocarcinoma. , 0, , 498-542.		0
255	Rare Tumors of the Liver. , 0, , 669-687.		0
256	Cystic Neoplasms of the Pancreas. , 0, , 688-710.		0
257	Molecular Biology of Gastroesophageal Cancers: The Role of Mutational Analysis in Prognosis. , 0, , 21-30.		0
258	Esophageal Adenocarcinoma. , 0, , 31-113.		0
259	Squamous Cancer of the Esophagus. , 0, , 114-145.		0
260	Diffuse Gastric Cancer. , 0, , 146-176.		0
261	Intestinal Gastric Cancer. , 0, , 177-188.		0
262	Small Bowel Tumors. , 0, , 189-226.		0
263	Sarcoma and Gastrointestinal Stromal Tumors. , 0, , 227-258.		0